<DOC>
	<DOCNO>NCT00501046</DOCNO>
	<brief_summary>1 ) To evaluate effectiveness AST-120 ( spherical carbon adsorbent ) add standard-of-care therapy moderate severe Chronic Kidney Disease ( CKD ) , time first occurrence event triple composite outcome initiation dialysis , kidney transplant double serum creatinine ( sCr ) compare placebo ; 2 ) To evaluate safety tolerability long-term AST-120 therapy patient CKD ; 3 ) To evaluate effect AST-120 versus placebo , measure renal function quality life .</brief_summary>
	<brief_title>A Study AST-120 Evaluating Prevention Progression In Chronic Kidney Disease Including Assessment Quality Life ( EPPIC-2 )</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Age 18 year old Moderate severe CKD , anticipate require dialysis renal transplant within next 6 month Patient survival expect less one year Serum creatinine men &gt; = 2.0 mg/dL ( &gt; = 177 µmol/L ) &lt; = 5.0 mg/dL ( &lt; = 442 µmol/L ) , woman &gt; = 1.5 mg/dL ( &gt; = 133 µmol/L ) &lt; = 5.0 mg/dL ( &lt; = 442 µmol/L ) Screening Urinary total protein urinary total creatinine ratio must &gt; = 0.5 spot void obtain Screening Blood pressure &lt; = 160/90 mmHg Screening Baseline visit . In addition , blood pressure , measure , must stable hypertensive patient 3 month prior Screening , 1 blood pressure read &gt; 160/90 mmHg In patient treated hypertension , stable antihypertensive regimen Obstructive reversible cause kidney disease Nephrotic syndrome define ratio urinary total protein urinary creatinine &gt; 6.0 measure spot void Adult polycystic kidney disease History previous kidney transplant History recent ( within past 6 month ) accelerate malignant hypertension Uncontrolled arrhythmia severe cardiac disease within past 6 month History malabsorption , inflammatory bowel disease , hiatal hernia , active peptic ulcer , severe GI dysmotility , attributable use phosphate binder Received investigational agent participate clinical study within previous 3 month Presence significant medical condition might create undue risk study participation , significantly confound collection safety efficacy data study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Kidney Diseases</keyword>
</DOC>